PL192348B1 - Stały środek farmaceutyczny do podawania doustnego - Google Patents
Stały środek farmaceutyczny do podawania doustnegoInfo
- Publication number
- PL192348B1 PL192348B1 PL337794A PL33779498A PL192348B1 PL 192348 B1 PL192348 B1 PL 192348B1 PL 337794 A PL337794 A PL 337794A PL 33779498 A PL33779498 A PL 33779498A PL 192348 B1 PL192348 B1 PL 192348B1
- Authority
- PL
- Poland
- Prior art keywords
- cyclodextrin
- cetirizine
- active ingredient
- oral administration
- group
- Prior art date
Links
- 229920000858 Cyclodextrin Polymers 0.000 title claims abstract description 64
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 title claims abstract description 25
- 239000013543 active substance Substances 0.000 title claims abstract description 9
- 239000003795 chemical substances by application Substances 0.000 title description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 15
- 150000008640 diphenylmethylpiperazines Chemical class 0.000 claims abstract description 12
- ZKLPARSLTMPFCP-UHFFFAOYSA-N Cetirizine Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-UHFFFAOYSA-N 0.000 claims description 39
- 229960001803 cetirizine Drugs 0.000 claims description 36
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims description 30
- 239000001116 FEMA 4028 Substances 0.000 claims description 28
- 235000011175 beta-cyclodextrine Nutrition 0.000 claims description 28
- 229960004853 betadex Drugs 0.000 claims description 28
- 239000004480 active ingredient Substances 0.000 claims description 21
- 238000000034 method Methods 0.000 claims description 12
- 150000001875 compounds Chemical class 0.000 claims description 10
- 239000007910 chewable tablet Substances 0.000 claims description 8
- ZQDWXGKKHFNSQK-UHFFFAOYSA-N hydroxyzine Chemical compound C1CN(CCOCCO)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZQDWXGKKHFNSQK-UHFFFAOYSA-N 0.000 claims description 8
- 239000008187 granular material Substances 0.000 claims description 7
- 239000006188 syrup Substances 0.000 claims description 7
- 235000020357 syrup Nutrition 0.000 claims description 7
- 229960000930 hydroxyzine Drugs 0.000 claims description 6
- 239000006190 sub-lingual tablet Substances 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 4
- BAWMMJAUVBLLEE-UHFFFAOYSA-N 2-[2-[4-[bis(4-fluorophenyl)methyl]piperazin-1-yl]ethoxy]acetic acid Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(F)=CC=1)C1=CC=C(F)C=C1 BAWMMJAUVBLLEE-UHFFFAOYSA-N 0.000 claims description 3
- 125000000217 alkyl group Chemical group 0.000 claims description 3
- 229950003420 efletirizine Drugs 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 3
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 claims description 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 2
- 239000006069 physical mixture Substances 0.000 claims description 2
- 239000000243 solution Substances 0.000 description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 238000010521 absorption reaction Methods 0.000 description 9
- 235000019658 bitter taste Nutrition 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 239000000546 pharmaceutical excipient Substances 0.000 description 9
- 235000019640 taste Nutrition 0.000 description 9
- 230000000873 masking effect Effects 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 6
- 239000000796 flavoring agent Substances 0.000 description 5
- 235000019634 flavors Nutrition 0.000 description 5
- 239000002696 acid base indicator Substances 0.000 description 4
- 238000010668 complexation reaction Methods 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 229910002016 Aerosil® 200 Inorganic materials 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 239000000739 antihistaminic agent Substances 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- 230000009918 complex formation Effects 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 229920005862 polyol Polymers 0.000 description 3
- 150000003077 polyols Chemical class 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 2
- 229920002785 Croscarmellose sodium Polymers 0.000 description 2
- OCJYIGYOJCODJL-UHFFFAOYSA-N Meclizine Chemical compound CC1=CC=CC(CN2CCN(CC2)C(C=2C=CC=CC=2)C=2C=CC(Cl)=CC=2)=C1 OCJYIGYOJCODJL-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 238000000862 absorption spectrum Methods 0.000 description 2
- 239000000619 acesulfame-K Substances 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 230000001387 anti-histamine Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 229960001681 croscarmellose sodium Drugs 0.000 description 2
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 229940097362 cyclodextrins Drugs 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 150000002431 hydrogen Chemical class 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- STZCRXQWRGQSJD-GEEYTBSJSA-M methyl orange Chemical compound [Na+].C1=CC(N(C)C)=CC=C1\N=N\C1=CC=C(S([O-])(=O)=O)C=C1 STZCRXQWRGQSJD-GEEYTBSJSA-M 0.000 description 2
- 229940012189 methyl orange Drugs 0.000 description 2
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 2
- 239000001253 polyvinylpolypyrrolidone Substances 0.000 description 2
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 2
- 238000001429 visible spectrum Methods 0.000 description 2
- GBBSUAFBMRNDJC-MRXNPFEDSA-N (5R)-zopiclone Chemical compound C1CN(C)CCN1C(=O)O[C@@H]1C2=NC=CN=C2C(=O)N1C1=CC=C(Cl)C=N1 GBBSUAFBMRNDJC-MRXNPFEDSA-N 0.000 description 1
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 1
- UZKBSZSTDQSMDR-UHFFFAOYSA-N 1-[(4-chlorophenyl)-phenylmethyl]piperazine Chemical class C1=CC(Cl)=CC=C1C(C=1C=CC=CC=1)N1CCNCC1 UZKBSZSTDQSMDR-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- KPPOZKAGJSXVND-UHFFFAOYSA-N 3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-n,n,2-trimethylpropan-1-amine;methanesulfonic acid Chemical compound CS(O)(=O)=O.C1CC2=CC=CC=C2N(CC(CN(C)C)C)C2=CC=CC=C21 KPPOZKAGJSXVND-UHFFFAOYSA-N 0.000 description 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
- 239000005449 Avicel CE Substances 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 244000303040 Glycyrrhiza glabra Species 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- ILRKKHJEINIICQ-OOFFSTKBSA-N Monoammonium glycyrrhizinate Chemical compound N.O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O ILRKKHJEINIICQ-OOFFSTKBSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- HVWGGPRWKSHASF-UHFFFAOYSA-N Sulfuric acid, monooctadecyl ester Chemical compound CCCCCCCCCCCCCCCCCCOS(O)(=O)=O HVWGGPRWKSHASF-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- -1 alkyl sulfate salt Chemical class 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- MOYGZHXDRJNJEP-UHFFFAOYSA-N buclizine Chemical compound C1=CC(C(C)(C)C)=CC=C1CN1CCN(C(C=2C=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1 MOYGZHXDRJNJEP-UHFFFAOYSA-N 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229940068682 chewable tablet Drugs 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000000599 controlled substance Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000007922 dissolution test Methods 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 235000011477 liquorice Nutrition 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960001474 meclozine Drugs 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 1
- 229960002695 phenobarbital Drugs 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 229960001108 trimipramine mesylate Drugs 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
- 235000005282 vitamin D3 Nutrition 0.000 description 1
- 239000011647 vitamin D3 Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940021056 vitamin d3 Drugs 0.000 description 1
- 229960000820 zopiclone Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nanotechnology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Physiology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Medical Informatics (AREA)
- Nutrition Science (AREA)
- Crystallography & Structural Chemistry (AREA)
- Pulmonology (AREA)
- Zoology (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| BE9700572A BE1011251A3 (fr) | 1997-07-03 | 1997-07-03 | Compositions pharmaceutiques administrables par voie orale, comprenant une substance active et une cyclodextrine. |
| PCT/BE1998/000100 WO1999001133A1 (fr) | 1997-07-03 | 1998-07-02 | Compositions pharmaceutiques administrables par voie orale, comprenant une substance active et une cyclodextrine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PL337794A1 PL337794A1 (en) | 2000-09-11 |
| PL192348B1 true PL192348B1 (pl) | 2006-10-31 |
Family
ID=3890611
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL337794A PL192348B1 (pl) | 1997-07-03 | 1998-07-02 | Stały środek farmaceutyczny do podawania doustnego |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US6455533B1 (enExample) |
| EP (1) | EP0994710B2 (enExample) |
| JP (2) | JP2002508773A (enExample) |
| KR (1) | KR100551510B1 (enExample) |
| CN (1) | CN1150900C (enExample) |
| AT (1) | ATE224717T1 (enExample) |
| AU (1) | AU727140B2 (enExample) |
| BE (1) | BE1011251A3 (enExample) |
| BR (1) | BR9810495A (enExample) |
| CA (1) | CA2294783C (enExample) |
| DE (1) | DE69808297T3 (enExample) |
| DK (1) | DK0994710T4 (enExample) |
| ES (1) | ES2184293T5 (enExample) |
| ID (1) | ID23806A (enExample) |
| IL (1) | IL133397A (enExample) |
| NZ (1) | NZ501820A (enExample) |
| PL (1) | PL192348B1 (enExample) |
| PT (1) | PT994710E (enExample) |
| RU (1) | RU2192863C2 (enExample) |
| WO (1) | WO1999001133A1 (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0028575D0 (en) * | 2000-11-23 | 2001-01-10 | Elan Corp Plc | Oral pharmaceutical compositions containing cyclodextrins |
| US20040213839A1 (en) * | 2001-02-05 | 2004-10-28 | Andrew Favara | Methods and compositions for reducing the taste of pharmaceutically active agents |
| NZ534039A (en) * | 2002-01-15 | 2006-08-31 | Ucb Farchim S | Formulations of pharmaceutical compositions for oral administration |
| PL372904A1 (en) * | 2002-04-04 | 2005-08-08 | Pfizer Products Inc. | Palatable chewable tablet |
| CA2574602A1 (en) * | 2004-07-22 | 2006-02-02 | Pfizer Products Inc. | Taste masking formulation comprising the drug in a dissolution-retarded form and/or cyclodextrin in a dissolution-enhanced form |
| US20060147518A1 (en) * | 2004-12-30 | 2006-07-06 | Pierre Fabre Medicament | Stable solid dispersion of a derivative of vinca alkaloid and process for manufacturing it |
| US20060198885A1 (en) * | 2005-02-22 | 2006-09-07 | Sun Pharmaceutical Industries Ltd. | Oral pharmaceutical composition |
| US20070086974A1 (en) * | 2005-10-06 | 2007-04-19 | Gawande Rahul S | Cetirizine compositions |
| US20090269393A1 (en) * | 2006-06-12 | 2009-10-29 | Jubliant Organosys Limited | Chewable Bilayer Tablet Formulation |
| JP2008143807A (ja) * | 2006-12-07 | 2008-06-26 | Sato Pharmaceutical Co Ltd | 感冒薬カプセル剤及びその製造方法 |
| EP2550967A1 (en) * | 2007-07-11 | 2013-01-30 | Fertin Pharma A/S | Compressed chewing gum tablet comprising taste-masking agent |
| US20100260818A1 (en) * | 2007-07-11 | 2010-10-14 | Fertin Pharma A/S | Stable medicated chewing gum comprising cyclodextrin inclusion complex |
| WO2009054432A1 (ja) * | 2007-10-26 | 2009-04-30 | Daiichi Sankyo Company, Limited | 口腔内速崩壊性医薬組成物およびその製造方法 |
| US8138192B2 (en) * | 2007-10-31 | 2012-03-20 | Genebiology, Inc. | Injectable meclizine formulations and methods |
| WO2009061465A1 (en) * | 2007-11-06 | 2009-05-14 | Teva Pharmaceutical Industries Ltd. | Chewable formulations |
| ES2564056T3 (es) * | 2008-09-05 | 2016-03-17 | Johnson & Johnson Consumer Inc. | Método para hacer pastillas de cetirizina |
| WO2011110939A2 (en) | 2010-03-11 | 2011-09-15 | Rubicon Research Private Limited | Pharmaceutical compositions of substituted benzhydrylpiperazines |
| WO2011150859A1 (en) * | 2010-06-04 | 2011-12-08 | Comprehensive Drug Enterprises Ltd | Oral meclizine aqueous formulations with taste flavoring agent |
| CN101905027A (zh) * | 2010-07-27 | 2010-12-08 | 北京华禧联合科技发展有限公司 | 含米格列奈钙和环糊精的口服药用组合物 |
| AU2011302293B2 (en) | 2010-09-13 | 2015-11-26 | Bev-Rx, Inc. | Aqueous drug delivery system comprising off - flavor masking agent |
| US9945862B2 (en) | 2011-06-03 | 2018-04-17 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds |
| RU2589833C2 (ru) * | 2013-12-12 | 2016-07-10 | Общество С Ограниченной Ответственностью "Фарма Старт" | Твердая лекарственная форма препарата седативного и снотворного действия |
| DK3122330T3 (en) * | 2014-03-27 | 2018-10-22 | Ucb Farchim Sa | Pharmaceutical compositions comprising levocetirizine |
| IL302218B2 (en) | 2014-08-28 | 2024-10-01 | Eisai R&D Man Co Ltd | Methods for manufacturing high-purity lenvatinib and its derivatives |
| JP6792546B2 (ja) | 2015-02-25 | 2020-11-25 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | キノリン誘導体の苦味抑制方法 |
| AU2015384801B2 (en) | 2015-03-04 | 2022-01-06 | Eisai R&D Management Co., Ltd. | Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer |
| EP3311841B1 (en) | 2015-06-16 | 2021-07-28 | PRISM BioLab Co., Ltd. | Anticancer agent |
| CN108135894B (zh) | 2015-08-20 | 2021-02-19 | 卫材R&D管理有限公司 | 肿瘤治疗剂 |
| RU2750539C2 (ru) | 2017-02-08 | 2021-06-29 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Фармацевтическая композиция для лечения опухоли |
| AU2018269996A1 (en) | 2017-05-16 | 2019-11-21 | Eisai R&D Management Co., Ltd. | Treatment of hepatocellular carcinoma |
| KR102110304B1 (ko) * | 2017-06-30 | 2020-05-14 | 한미약품 주식회사 | 레보세티리진 및 몬테루카스트를 포함하는 안정성 및 복약순응도가 향상된 복합 츄어블정 및 그 제조방법 |
| EP4099977A1 (en) * | 2020-02-03 | 2022-12-14 | Johnson & Johnson Consumer Inc. | A single layer chewable tablet comprising cetirizine |
| WO2022106923A1 (en) | 2020-11-18 | 2022-05-27 | BioPharma Synergies, S. L. | Orodispersible powder composition comprising an antihistamine compound |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK154078C (da) * | 1981-02-06 | 1989-05-22 | Ucb Sa | Analogifremgangsmaade til fremstilling af 2-(2-(4-(diphenyl-methyl)-1-piperazinyl)ethoxy)-acetamider eller syreadditionssalte heraf |
| JPS58177949A (ja) * | 1982-04-12 | 1983-10-18 | Takeda Chem Ind Ltd | ランカシジン群抗生物質包接化合物 |
| JPS60204712A (ja) * | 1984-03-29 | 1985-10-16 | Ss Pharmaceut Co Ltd | 塩酸メクリジンの安定化液状組成物 |
| JPS63243031A (ja) † | 1987-03-28 | 1988-10-07 | Tokyo Tanabe Co Ltd | 胆汁酸の固形製剤 |
| FR2647343B1 (fr) * | 1989-05-24 | 1994-05-06 | Rhone Poulenc Sante | Nouvelle forme pharmaceutique poreuse et sa preparation |
| US5206025A (en) * | 1989-05-24 | 1993-04-27 | Rhone-Poulenc Sante | Porous pharmaceutical form and its preparation |
| CA2145410A1 (en) † | 1992-09-24 | 1994-03-31 | Nancy M. Gray | Compositions for treating allergic disorders using (-) cetirizine |
| TW401300B (en) * | 1992-12-25 | 2000-08-11 | Senju Pharma Co | Antiallergic composition for ophthalmic or nasal use |
| ES2166811T3 (es) * | 1993-12-01 | 2002-05-01 | Byk Gulden Lomberg Chem Fab | Amino-alquil-amino-piridinas sustituidas. |
| US5866179A (en) | 1996-05-03 | 1999-02-02 | Avant-Garde Technologies & Products S.A. | Medicated chewing gum and a process for preparation thereof |
| GB0028575D0 (en) * | 2000-11-23 | 2001-01-10 | Elan Corp Plc | Oral pharmaceutical compositions containing cyclodextrins |
| CA2574602A1 (en) * | 2004-07-22 | 2006-02-02 | Pfizer Products Inc. | Taste masking formulation comprising the drug in a dissolution-retarded form and/or cyclodextrin in a dissolution-enhanced form |
-
1997
- 1997-07-03 BE BE9700572A patent/BE1011251A3/fr not_active IP Right Cessation
-
1998
- 1998-07-02 IL IL13339798A patent/IL133397A/xx not_active IP Right Cessation
- 1998-07-02 AU AU82015/98A patent/AU727140B2/en not_active Expired
- 1998-07-02 RU RU99128065/14A patent/RU2192863C2/ru not_active IP Right Cessation
- 1998-07-02 PL PL337794A patent/PL192348B1/pl not_active IP Right Cessation
- 1998-07-02 JP JP50598499A patent/JP2002508773A/ja not_active Withdrawn
- 1998-07-02 DE DE69808297T patent/DE69808297T3/de not_active Expired - Lifetime
- 1998-07-02 CN CNB988067641A patent/CN1150900C/zh not_active Expired - Lifetime
- 1998-07-02 ES ES98931849T patent/ES2184293T5/es not_active Expired - Lifetime
- 1998-07-02 CA CA002294783A patent/CA2294783C/fr not_active Expired - Fee Related
- 1998-07-02 WO PCT/BE1998/000100 patent/WO1999001133A1/fr not_active Ceased
- 1998-07-02 DK DK98931849T patent/DK0994710T4/da active
- 1998-07-02 AT AT98931849T patent/ATE224717T1/de active
- 1998-07-02 KR KR1019997012573A patent/KR100551510B1/ko not_active Expired - Fee Related
- 1998-07-02 NZ NZ501820A patent/NZ501820A/xx unknown
- 1998-07-02 BR BR9810495-0A patent/BR9810495A/pt not_active Application Discontinuation
- 1998-07-02 PT PT98931849T patent/PT994710E/pt unknown
- 1998-07-02 EP EP98931849A patent/EP0994710B2/fr not_active Expired - Lifetime
- 1998-07-02 US US09/446,735 patent/US6455533B1/en not_active Expired - Lifetime
- 1998-07-02 ID IDW991729A patent/ID23806A/id unknown
-
2007
- 2007-01-12 JP JP2007004722A patent/JP2007091760A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| DE69808297D1 (de) | 2002-10-31 |
| AU727140B2 (en) | 2000-12-07 |
| KR100551510B1 (ko) | 2006-02-13 |
| PT994710E (pt) | 2003-02-28 |
| NZ501820A (en) | 2000-10-27 |
| CA2294783A1 (fr) | 1999-01-14 |
| EP0994710A1 (fr) | 2000-04-26 |
| US20020032217A1 (en) | 2002-03-14 |
| JP2002508773A (ja) | 2002-03-19 |
| ES2184293T5 (es) | 2006-01-16 |
| DK0994710T4 (da) | 2005-10-17 |
| JP2007091760A (ja) | 2007-04-12 |
| PL337794A1 (en) | 2000-09-11 |
| ID23806A (id) | 2000-05-11 |
| DE69808297T3 (de) | 2006-01-19 |
| AU8201598A (en) | 1999-01-25 |
| US6455533B1 (en) | 2002-09-24 |
| CN1261799A (zh) | 2000-08-02 |
| KR20010014398A (ko) | 2001-02-26 |
| DK0994710T3 (da) | 2003-01-20 |
| EP0994710B1 (fr) | 2002-09-25 |
| IL133397A0 (en) | 2001-04-30 |
| BE1011251A3 (fr) | 1999-06-01 |
| CN1150900C (zh) | 2004-05-26 |
| BR9810495A (pt) | 2000-09-12 |
| WO1999001133A1 (fr) | 1999-01-14 |
| ES2184293T3 (es) | 2003-04-01 |
| IL133397A (en) | 2005-07-25 |
| CA2294783C (fr) | 2006-11-14 |
| RU2192863C2 (ru) | 2002-11-20 |
| EP0994710B2 (fr) | 2005-09-21 |
| ATE224717T1 (de) | 2002-10-15 |
| DE69808297T2 (de) | 2003-04-17 |
| HK1029060A1 (en) | 2001-03-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL192348B1 (pl) | Stały środek farmaceutyczny do podawania doustnego | |
| KR100311576B1 (ko) | 경구투여용 항균성 조성물 | |
| JPH0370705B2 (enExample) | ||
| PL212123B1 (pl) | Doustna kompozycja farmaceutyczna | |
| JP2002503267A (ja) | スルホアルキルエーテルシクロデキストリンと治療剤との物理的混合物を含有する固形製剤 | |
| IL195417A (en) | Oral compound containing 3 - [5 - [4 - (cyclopentyloxy) - 2 - hydroxybenzoyl] -2 - [(3 - hydroxy - 2,1 - benzysoxazole - 6 - yl) methoxy] phenyl] propionic acid or salt thereof | |
| ES2622568T3 (es) | Comprimido que contiene 5-hidroxi-1H-imidazol-4-carboxamida | |
| Chowdary et al. | Controlled release of nifedipine from mucoadhesive tablets of its inclusion complexes with β-cyclodextrin | |
| MXPA99011899A (en) | Pharmaceutical compositions for oral administration, comprising an active substance and a cyclodextrin | |
| Becirevic | Brussels (BE); Michel Deleers, Linkebeek (BE) FOREIGN PATENT DOCUMENTS | |
| HK1029060B (en) | Pharmaceutical compositions for oral administration, comprising an active substance and a cyclodextrin | |
| US5712260A (en) | Estramustine formulations with improved pharmaceutical properties | |
| Mahapatra et al. | Solubility enhancement of etoricoxib using inclusion complexation with cyclodextrins: formulation of oro dispersible tablets by QbD approach | |
| Dhakal et al. | Research Article Formulation of Ebastine Fast-Disintegrating Tablet Using Coprocessed Superdisintegrants and Evaluation of Quality Control Parameters | |
| EP4504207A1 (en) | An orodispersible tablet of rivaroxaban | |
| JP2025524177A (ja) | ドロタベリンの口腔内崩壊性嗜好性製剤及びその調製方法 | |
| CN116173236A (zh) | 一种常山酮磺丁基醚环糊精包合物及其制备方法 | |
| RU2237478C2 (ru) | Антимикробная фармацевтическая композиция | |
| WO2023101620A1 (en) | Delayed release composition comprising doxylamine and pyridoxine | |
| Deshmukh Sambhaji et al. | APTI ijper | |
| Zalaki | Formulation and Evaluation of Ternary System for Solubility Enhancement of a Second Generation Cox-II Inhibitior | |
| Pandya | Formulation and Evaluation of controlled release matrix Tablets of Glipizide | |
| CS227689B2 (cs) | Způsob výroby uzavřených komplexů N-(1-fenyiethyl)-3,3-difenylpropytaminu nebo jeho hydrochloridu s cyklodextrinem | |
| HUP0100028A2 (en) | Oral pharmaceutical compositions containing sildenafil with cyclodextrins |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| LAPS | Decisions on the lapse of the protection rights |
Effective date: 20130702 |